Harvard Biosci Financials
Harvard Biosci (HBIO) reported $86.5M in revenue for fiscal year 2025, down 8.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A non-cash balance-sheet reset dominated FY2025, crushing reported earnings while operating cash flow and free cash still stayed positive.
FY2025 net income fell to-$56.7M while operating cash flow rose to$6.7M , so accounting loss and cash generation sharply diverged. That gap lines up with goodwill shrinking from$56.3M to$9.6M , pointing to a non-cash impairment-heavy year rather than an equally large cash drain.
Revenue has fallen for two straight years, reaching
The balance sheet got easier in the short term: the current ratio recovered to 2.2x in FY2025 from 0.8x in FY2024 as cash rose and near-term obligations fell. But equity fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Harvard Biosci's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Harvard Biosci, and counted as zero in the overall score.
Harvard Biosci scores -3.97, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($34.8M) relative to total liabilities ($66.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Harvard Biosci passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Harvard Biosci reported a net loss of $56.7M while generating $6.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Harvard Biosci reported an operating loss of $48.6M against $1.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Harvard Biosci generated $86.5M in revenue in fiscal year 2025. This represents a decrease of 8.1% from the prior year.
Harvard Biosci's EBITDA was -$42.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5652.5% from the prior year.
Harvard Biosci reported -$56.7M in net income in fiscal year 2025. This represents a decrease of 357.1% from the prior year.
Harvard Biosci earned -$1.28 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 357.1% from the prior year.
Cash & Balance Sheet
Harvard Biosci generated $5.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 554.4% from the prior year.
Harvard Biosci held $8.6M in cash against $35.9M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Harvard Biosci's gross margin was 57.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.5 percentage points from the prior year.
Harvard Biosci's operating margin was -56.1% in fiscal year 2025, reflecting core business profitability. This is down 49.5 percentage points from the prior year.
Harvard Biosci's net profit margin was -65.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 52.3 percentage points from the prior year.
Harvard Biosci's ROE was -412.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 393.3 percentage points from the prior year.
Capital Allocation
Harvard Biosci invested $8.8M in research and development in fiscal year 2025. This represents a decrease of 15.2% from the prior year.
Harvard Biosci invested $1.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 52.4% from the prior year.
Not reported for fiscal year 2025.
HBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $87.8M | $86.5M-8.1% | $94.1M-16.1% | $112.3M-1.0% | $113.3M-4.7% | $118.9M+16.5% | $102.1M-12.1% | $116.2M-3.8% | $120.8M+56.0% | $77.4M-25.9% | $104.5M-3.8% | $108.7M0.0% | $108.7M+3.3% | $105.2M-5.4% | $111.2M+2.1% | $108.9M |
| Cost of Revenue | $36.7M | $36.6M-6.9% | $39.4M-14.7% | $46.2M-12.1% | $52.5M+2.5% | $51.3M+16.3% | $44.1M-15.0% | $51.9M-10.0% | $57.6M+50.6% | $38.2M-31.8% | $56.1M-6.4% | $59.9M+1.0% | $59.3M+3.2% | $57.5M-2.3% | $58.8M+0.3% | $58.7M |
| Gross Profit | $51.1M | $49.9M-8.9% | $54.8M-17.1% | $66.1M+8.6% | $60.8M-10.1% | $67.7M+16.6% | $58.0M-9.8% | $64.3M+1.8% | $63.2M+61.3% | $39.2M-19.1% | $48.4M-0.6% | $48.7M-1.3% | $49.3M+3.5% | $47.7M-8.9% | $52.3M+4.3% | $50.2M |
| R&D Expenses | $9.1M | $8.8M-15.2% | $10.4M-11.5% | $11.8M-4.6% | $12.3M+14.2% | $10.8M+24.3% | $8.7M-18.9% | $10.7M-2.5% | $11.0M+94.7% | $5.6M+4.7% | $5.4M-16.0% | $6.4M+31.6% | $4.9M+17.5% | $4.2M-4.4% | $4.3M+12.1% | $3.9M |
| SG&A Expenses | $17.6M | $17.7M-17.5% | $21.5M-5.6% | $22.8M-7.1% | $24.5M+0.8% | $24.3M+3.4% | $23.5M+3.3% | $22.8M+6.4% | $21.4M+22.0% | $17.5M-16.3% | $20.9M+5.6% | $19.8M+17.9% | $16.8M-5.9% | $17.9M-1.3% | $18.1M+2.8% | $17.6M |
| Operating Income | -$245K | -$48.6M-682.2% | -$6.2M-427.9% | $1.9M+127.3% | -$6.9M-435.6% | $2.1M+834.8% | $221K-41.4% | $377K-61.7% | $984K+255.0% | -$635K+78.8% | -$3.0M-75.0% | -$1.7M-125.9% | $6.6M+330.6% | $1.5M-80.4% | $7.8M-6.8% | $8.4M |
| Interest Expense | N/A | $1.3M+62.5% | $800K | N/A | N/A | N/A | N/A | N/A | $5.4M+652.7% | $713K+11.6% | $639K-24.5% | $846K-14.5% | $990K+3.7% | $955K+63.5% | $584K-22.3% | $752K |
| Income Tax | -$129K | -$686K-192.7% | $740K-13.9% | $859K+154.9% | $337K+127.7% | $148K-71.4% | $518K+163.6% | -$815K+77.8% | -$3.7M-507.6% | -$605K-149.2% | $1.2M-92.0% | $15.4M+648.4% | $2.1M+816.0% | -$288K-112.0% | $2.4M+51.9% | $1.6M |
| Net Income | -$10.4M | -$56.7M-357.1% | -$12.4M-263.3% | -$3.4M+64.1% | -$9.5M-3204.2% | -$288K+96.3% | -$7.8M-66.6% | -$4.7M-60.4% | -$2.9M-237.8% | -$865K+79.9% | -$4.3M+77.4% | -$19.0M-908.5% | $2.4M+228.7% | -$1.8M-177.2% | $2.4M-37.8% | $3.8M |
| EPS (Diluted) | — | -$1.28-357.1% | -$0.28-250.0% | -$0.08+65.2% | -$0.23 | N/A | N/A | -$0.12-50.0% | -$0.08-300.0% | -$0.02+84.6% | -$0.13+77.2% | -$0.57-914.3% | $0.07+216.7% | -$0.06-175.0% | $0.08-38.5% | $0.13 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
HBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $80.1M-36.8% | $126.6M-7.8% | $137.4M-5.5% | $145.4M-10.5% | $162.3M+3.9% | $156.3M-5.2% | $164.9M-2.2% | $168.6M+54.2% | $109.4M+1.5% | $107.8M-10.2% | $120.0M-11.7% | $135.9M+0.3% | $135.5M+1.5% | $133.5M+5.4% | $126.6M |
| Current Assets | $48.2M+6.9% | $45.1M-8.0% | $49.0M-4.1% | $51.1M-17.0% | $61.6M+19.1% | $51.7M-3.5% | $53.6M-7.4% | $57.8M+21.7% | $47.5M+4.5% | $45.5M-10.0% | $50.5M-11.4% | $57.1M-6.1% | $60.8M+3.0% | $59.0M+2.4% | $57.6M |
| Cash & Equivalents | $8.6M+109.7% | $4.1M-4.1% | $4.3M-5.0% | $4.5M-42.4% | $7.8M-6.0% | $8.3M-0.2% | $8.3M+2.0% | $8.2M+42.6% | $5.7M+2.4% | $5.6M-17.0% | $6.7M-52.3% | $14.1M-45.2% | $25.8M+24.6% | $20.7M+15.4% | $17.9M |
| Inventory | $20.8M-10.5% | $23.2M-6.0% | $24.7M-6.5% | $26.4M-4.2% | $27.6M+23.9% | $22.3M+0.9% | $22.1M-12.1% | $25.1M+48.9% | $16.8M-15.6% | $20.0M-10.7% | $22.3M+8.8% | $20.5M+30.1% | $15.8M-11.2% | $17.8M-2.2% | $18.2M |
| Accounts Receivable | $16.0M+7.9% | $14.9M-7.7% | $16.1M-3.6% | $16.7M-23.5% | $21.8M+22.9% | $17.8M-14.2% | $20.7M-3.5% | $21.5M+60.4% | $13.4M-15.0% | $15.7M-10.3% | $17.5M+8.7% | $16.1M+16.3% | $13.9M-3.3% | $14.4M-4.8% | $15.1M |
| Goodwill | $9.6M-83.0% | $56.3M-1.3% | $57.1M+1.4% | $56.3M-2.5% | $57.7M-1.5% | $58.6M+2.1% | $57.4M+0.1% | $57.3M+57.7% | $36.3M-4.5% | $38.0M-5.8% | $40.4M+1.3% | $39.8M+8.8% | $36.6M+1.1% | $36.2M+5.8% | $34.2M |
| Total Liabilities | $66.3M+4.8% | $63.3M-1.5% | $64.3M-12.1% | $73.1M-7.4% | $78.9M-0.8% | $79.6M-4.3% | $83.2M-3.2% | $85.9M+201.9% | $28.5M-20.0% | $35.6M-16.2% | $42.5M+5.0% | $40.4M-1.3% | $41.0M+40.0% | $29.3M-6.0% | $31.1M |
| Current Liabilities | $22.0M-60.0% | $55.0M+107.1% | $26.5M+14.2% | $23.2M-8.2% | $25.3M+20.2% | $21.1M-16.8% | $25.3M-0.7% | $25.5M+81.5% | $14.0M-3.8% | $14.6M-24.4% | $19.3M+6.8% | $18.1M+12.5% | $16.1M+62.5% | $9.9M+3.6% | $9.6M |
| Long-Term Debt | $35.9M | N/A | $30.7M-28.6% | $43.0M-4.6% | $45.1M-2.6% | $46.3M-1.3% | $46.9M-14.4% | $54.8M+510.2% | $9.0M-21.0% | $11.4M-30.5% | $16.4M-0.5% | $16.4M-16.7% | $19.8M+52.5% | $12.9M-20.6% | $16.3M |
| Total Equity | $13.7M-78.3% | $63.3M-13.3% | $73.1M+1.2% | $72.2M-13.4% | $83.4M+8.8% | $76.7M-6.1% | $81.7M-1.2% | $82.7M+2.3% | $80.9M+12.1% | $72.2M-7.0% | $77.6M-18.7% | $95.5M+1.0% | $94.5M-9.3% | $104.2M+9.1% | $95.5M |
| Retained Earnings | -$214.7M-35.9% | -$158.0M-8.5% | -$145.6M-2.4% | -$142.2M-7.2% | -$132.7M-0.2% | -$132.4M-6.3% | -$124.6M-3.9% | -$119.9M-2.5% | -$117.0M-0.8% | -$116.0M-3.9% | -$111.7M-20.5% | -$92.7M+2.5% | -$95.0M-23.0% | -$77.3M+3.0% | -$79.6M |
HBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $651K | $6.7M+367.3% | $1.4M-89.7% | $14.0M+1117.7% | $1.2M-8.7% | $1.3M-86.5% | $9.3M+16.0% | $8.0M+179.0% | $2.9M+172.8% | $1.1M-80.4% | $5.4M+663.5% | $705K-83.8% | $4.4M+7.2% | $4.1M-49.6% | $8.1M+21.3% | $6.6M |
| Capital Expenditures | $1.8M | $1.3M-52.4% | $2.6M+47.9% | $1.8M+12.5% | $1.6M+33.1% | $1.2M+3.7% | $1.2M-5.3% | $1.2M+23.3% | $986K+10.8% | $890K | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$1.1M | $5.5M+554.4% | -$1.2M-109.8% | $12.2M+2894.5% | -$438K-753.7% | $67K-99.2% | $8.2M+19.8% | $6.8M+259.8% | $1.9M+1036.5% | $167K | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$2.5M | -$1.9M-38.6% | -$1.3M+25.3% | -$1.8M-13.1% | -$1.6M-18.2% | -$1.3M+4.1% | -$1.4M-512.2% | -$229K+99.6% | -$53.8M-5766.5% | -$917K-1379.0% | -$62K+99.2% | -$7.5M+44.4% | -$13.5M-8004.7% | $171K+103.7% | -$4.7M+35.0% | -$7.2M |
| Financing Cash Flow | $1.1M | -$1.3M-885.5% | -$131K+98.9% | -$12.1M-327.7% | -$2.8M-1025.8% | -$252K+96.8% | -$8.0M-4.5% | -$7.6M-114.4% | $53.1M+3060.5% | -$1.8M+63.2% | -$4.9M-801.5% | -$540K+56.2% | -$1.2M-1914.7% | $68K+106.4% | -$1.1M+6.8% | -$1.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
HBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.7%-0.5pp | 58.2%-0.7pp | 58.9%+5.2pp | 53.7%-3.2pp | 56.9%0.0pp | 56.9%+1.5pp | 55.4%+3.1pp | 52.3%+1.7pp | 50.6%+4.3pp | 46.3%+1.5pp | 44.8%-0.6pp | 45.4%+0.1pp | 45.4%-1.7pp | 47.1%+1.0pp | 46.1% |
| Operating Margin | -56.1%-49.5pp | -6.6%-8.3pp | 1.7%+7.8pp | -6.1%-7.9pp | 1.7%+1.5pp | 0.2%-0.1pp | 0.3%-0.5pp | 0.8%+1.6pp | -0.8%+2.0pp | -2.9%-1.3pp | -1.6%-7.7pp | 6.1%+4.6pp | 1.5%-5.6pp | 7.0%-0.7pp | 7.7% |
| Net Margin | -65.5%-52.3pp | -13.2%-10.1pp | -3.0%+5.4pp | -8.4%-8.2pp | -0.2%+7.4pp | -7.6%-3.6pp | -4.0%-1.6pp | -2.4%-1.3pp | -1.1%+3.0pp | -4.1%+13.4pp | -17.5%-19.7pp | 2.2%+3.9pp | -1.7%-3.9pp | 2.1%-1.4pp | 3.5% |
| Return on Equity | -412.8%-393.3pp | -19.6%-14.9pp | -4.7%+8.5pp | -13.2%-12.8pp | -0.4%+9.8pp | -10.2%-4.5pp | -5.7%-2.2pp | -3.5%-2.5pp | -1.1%+4.9pp | -6.0%+18.6pp | -24.5%-27.0pp | 2.5%+4.4pp | -1.9%-4.2pp | 2.3%-1.7pp | 4.0% |
| Return on Assets | -70.8%-61.0pp | -9.8%-7.3pp | -2.5%+4.1pp | -6.6%-6.4pp | -0.2%+4.8pp | -5.0%-2.2pp | -2.8%-1.1pp | -1.7%-0.9pp | -0.8%+3.2pp | -4.0%+11.9pp | -15.9%-17.6pp | 1.7%+3.1pp | -1.4%-3.1pp | 1.8%-1.2pp | 3.0% |
| Current Ratio | 2.20+1.4x | 0.82-1.0x | 1.85-0.4x | 2.20-0.2x | 2.430.0x | 2.46+0.3x | 2.12-0.2x | 2.27-1.1x | 3.39+0.3x | 3.11+0.5x | 2.62-0.5x | 3.15-0.6x | 3.78-2.2x | 5.96-0.1x | 6.02 |
| Debt-to-Equity | 2.61+1.6x | 1.00+0.6x | 0.42-0.2x | 0.60+0.1x | 0.54-0.1x | 0.600.0x | 0.57-0.1x | 0.66+0.6x | 0.110.0x | 0.16-0.1x | 0.210.0x | 0.170.0x | 0.21+0.1x | 0.120.0x | 0.17 |
| FCF Margin | 6.3%+7.6pp | -1.3%-12.2pp | 10.9%+11.3pp | -0.4%-0.4pp | 0.1%-8.0pp | 8.0%+2.1pp | 5.9%+4.3pp | 1.6%+1.3pp | 0.2% | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Where Harvard Biosci Ranks
Frequently Asked Questions
What is Harvard Biosci's annual revenue?
Harvard Biosci (HBIO) reported $86.5M in total revenue for fiscal year 2025. This represents a -8.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Harvard Biosci's revenue growing?
Harvard Biosci (HBIO) revenue declined by 8.1% year-over-year, from $94.1M to $86.5M in fiscal year 2025.
Is Harvard Biosci profitable?
No, Harvard Biosci (HBIO) reported a net income of -$56.7M in fiscal year 2025, with a net profit margin of -65.5%.
What is Harvard Biosci's EBITDA?
Harvard Biosci (HBIO) had EBITDA of -$42.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Harvard Biosci have?
As of fiscal year 2025, Harvard Biosci (HBIO) had $8.6M in cash and equivalents against $35.9M in long-term debt.
What is Harvard Biosci's gross margin?
Harvard Biosci (HBIO) had a gross margin of 57.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Harvard Biosci's operating margin?
Harvard Biosci (HBIO) had an operating margin of -56.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Harvard Biosci's net profit margin?
Harvard Biosci (HBIO) had a net profit margin of -65.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Harvard Biosci's return on equity (ROE)?
Harvard Biosci (HBIO) has a return on equity of -412.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Harvard Biosci's free cash flow?
Harvard Biosci (HBIO) generated $5.5M in free cash flow during fiscal year 2025. This represents a 554.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Harvard Biosci's operating cash flow?
Harvard Biosci (HBIO) generated $6.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Harvard Biosci's total assets?
Harvard Biosci (HBIO) had $80.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Harvard Biosci's capital expenditures?
Harvard Biosci (HBIO) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Harvard Biosci spend on research and development?
Harvard Biosci (HBIO) invested $8.8M in research and development during fiscal year 2025.
What is Harvard Biosci's current ratio?
Harvard Biosci (HBIO) had a current ratio of 2.20 as of fiscal year 2025, which is generally considered healthy.
What is Harvard Biosci's debt-to-equity ratio?
Harvard Biosci (HBIO) had a debt-to-equity ratio of 2.61 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Harvard Biosci's return on assets (ROA)?
Harvard Biosci (HBIO) had a return on assets of -70.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Harvard Biosci's Altman Z-Score?
Harvard Biosci (HBIO) has an Altman Z-Score of -3.97, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Harvard Biosci's Piotroski F-Score?
Harvard Biosci (HBIO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Harvard Biosci's earnings high quality?
Harvard Biosci (HBIO) reported a net loss of $56.7M while generating $6.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Harvard Biosci cover its interest payments?
Harvard Biosci (HBIO) reported an operating loss of $48.6M against $1.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Harvard Biosci?
Harvard Biosci (HBIO) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.